Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors

• Published in: Acta neuropathologica communications Vol. 12; no. 1; p. 61
• Main Authors: Cheng, Yijun, Dai, Yuting, Tang, Hao, Lu, Xingyu, Xie, Jing, Xie, Wanqun, Zhang, Qianqian, Liu, Yanting, Lin, Shaojian, Yao, Hong, Shang, Hanbing, Yang, Kun, Liu, Hongyi, Wu, Xuefeng, Zhang, Jianming, Zhang, Xun, Xue, Li, Wu, Zhe Bao
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.04.2024; BioMed Central; BMC
• Subjects: Analysis; Genes; HDACIs; Health aspects; High-throughput screening; Nrf2; Panobinostat; PitNETs; RNA; RNA sequencing; Tumors; Panobinostat; High-throughput screening; HDACIs; Nrf2; PitNETs
• DOI: 10.1186/s40478-024-01775-2
• ISSN: 2051-5960

We aimed to identify the druggable cell-intrinsic vulnerabilities and target-based drug therapies for PitNETs using the high-throughput drug screening (HTS) and genomic sequencing methods. We examined 9 patient-derived PitNET primary cells in HTS. Based on the screening results, the potential target genes were analyzed with genomic sequencing from a total of 180 PitNETs. We identified and verified one of the most potentially effective drugs, which targeted the Histone deacetylases (HDACs) both in in vitro and in vivo PitNET models. Further RNA sequencing revealed underlying molecular mechanisms following treatment with the representative HDACs inhibitor, Panobinostat. The HTS generated a total of 20,736 single-agent dose responses which were enriched among multiple inhibitors for various oncogenic targets, including HDACs, PI3K, mTOR, and proteasome. Among these drugs, HDAC inhibitors (HDACIs) were, on average, the most potent drug class. Further studies using in vitro, in vivo, and isolated PitNET primary cell models validated HDACIs, especially Panobinostat, as a promising therapeutic agent. Transcriptional surveys revealed substantial alterations to the Nrf2 signaling following Panobinostat treatment. Moreover, Nrf2 is highly expressed in PitNETs. The combination of Panobinostat and Nrf2 inhibitor ML385 had a synergistic effect on PitNET suppression. The current study revealed a class of effective anti-PitNET drugs, HDACIs, based on the HTS and genomic sequencing. One of the representative compounds, Panobinostat, may be a potential drug for PitNET treatment via Nrf2-mediated redox modulation. Combination of Panobinostat and ML385 further enhance the effectiveness for PitNET treatment.